PremiumThe FlyOrganogenesis price target raised to $7 from $6 at BTIG Organogenesis Holdings Reports Strong Q4 2024 Results Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M PremiumThe FlyOrganogenesis ‘commends’ final local coverage determinations Organogenesis Holdings Secures $130M Investment for Growth Organogenesis Reports Robust Third Quarter Growth PremiumThe FlyOrganogenesis provides update on Phase 3 trial of ReNu in knee osteoarthritis Is ORGO a Buy, Before Earnings? Organogenesis trial results show safety, efficacy of NuShield for DFUs 
